Literature DB >> 29480453

Reply to Braillon et al.: Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?

Pablo Barrio1, Lluisa Ortega2, Josep Guardia3, Carlos Roncero4,5, Lara Yuguero6, Antoni Gual2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29480453     DOI： 10.1007/s40261-018-0625-5

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  14 in total

Review 1.  Defining substance use disorders: do we really need more than heavy use?

Authors:  J Rehm; S Marmet; P Anderson; A Gual; L Kraus; D J Nutt; R Room; A V Samokhvalov; E Scafato; M Trapencieris; R W Wiers; G Gmel
Journal:  Alcohol Alcohol       Date:  2013-08-07       Impact factor: 2.826

2.  A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.

Authors:  Antoni Gual; Yuan He; Lars Torup; Wim van den Brink; Karl Mann
Journal:  Eur Neuropsychopharmacol       Date:  2013-04-03       Impact factor: 4.600

3.  Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.

Authors:  Wim van den Brink; Per Sørensen; Lars Torup; Karl Mann; Antoni Gual
Journal:  J Psychopharmacol       Date:  2014-03-26       Impact factor: 4.153

4.  Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.

Authors:  Clément Palpacuer; Renan Duprez; Alexandre Huneau; Clara Locher; Rémy Boussageon; Bruno Laviolle; Florian Naudet
Journal:  Addiction       Date:  2017-09-20       Impact factor: 6.526

Review 5.  The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis.

Authors:  Michael Roerecke; Janusz Kaczorowski; Sheldon W Tobe; Gerrit Gmel; Omer S M Hasan; Jürgen Rehm
Journal:  Lancet Public Health       Date:  2017-02-07

6.  Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.

Authors:  Karl Mann; Anna Bladström; Lars Torup; Antoni Gual; Wim van den Brink
Journal:  Biol Psychiatry       Date:  2012-12-11       Impact factor: 13.382

7.  Is controlled drinking an acceptable goal in the treatment of alcohol dependence? A survey of French alcohol specialists.

Authors:  A Luquiens; M Reynaud; H J Aubin
Journal:  Alcohol Alcohol       Date:  2011-07-18       Impact factor: 2.826

8.  Bringing patient-centered care to patients with alcohol use disorders.

Authors:  Katharine A Bradley; Daniel R Kivlahan
Journal:  JAMA       Date:  2014-05-14       Impact factor: 56.272

9.  Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?

Authors:  Alain Braillon; Francoise Taiebi; Amal Bernoussi
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

Review 10.  Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials.

Authors:  Clément Palpacuer; Bruno Laviolle; Rémy Boussageon; Jean Michel Reymann; Eric Bellissant; Florian Naudet
Journal:  PLoS Med       Date:  2015-12-22       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.